Table of contents

Abstracts

Friday 6th September 2024

Opening session (HYBRID): enigma variations

• 01 Lupus and hemophagocytic lymphohistiocytosis (5 September, 2024)

  Jessica Manson
• 02 Lupus and cancer (5 September, 2024)

  Sasha Bernatsky
• 03 Lupus and infections (5 September, 2024)

  Bregtje Lemkes
• 04 Lupus and vaccinations (5 September, 2024)

  Reşit Yıldırım

Opening session (HYBRID): keynote

• 05 Management of lupus in low-middle income countries (5 September, 2024)

  Sandra Navarra

Debate: cry me a rivaroxaban

• 06 The matter of the debate: this house believes that we should (follow the EMA guidelines and) avoid using DOACs in APS and SLE/APS (For) (5 September, 2024)

  Vittorio Pengo
• 07 The matter of the debate: this house believes that we should (follow the EMA guidelines and) avoid using DOACs in APS and SLE/APS (Against) (5 September, 2024)

  Hannah Cohen

Plenary I: lupus basic science – a hard day’s night

• 08 Genetics of systemic lupus erythematosus (5 September, 2024)

  Leonid Padyukov
• 09 B and T cell interaction regulation (5 September, 2024)

  Claudia Mauri
• 10 The role of type I interferon in inflammatory rheumatic diseases: more questions than answers (5 September, 2024)

  Thomas Dörner

Saturday 7th September 2024

Breakfast workshop

• 11 Meet the editor (5 September, 2024)

  Ronald van Vollenhoven

Interactive case study workshops

• 12 Managing cardiovascular and lung disease in lupus (5 September, 2024)

  Bernardo Pons-Estel
• 13 Managing cardiovascular and lung disease in lupus (5 September, 2024)

  Anisur Rahman
• 14 Managing hematological problems in lupus (5 September, 2024)

  Ricard Cervera
• 15 Managing hematological problems in lupus (5 September, 2024)

  Raquel Faria
• 16 Managing skin Disease in SLE (5 September, 2024)

  Andrea Doria
• 17 Managing skin disease in SLE (5 September, 2024)

  Annegret Kuhn
• 18 Managing pregnancy in lupus (5 September, 2024)

  Sandra Navarra
• 19 Managing pregnancy in lupus (5 September, 2024)

  Irene Bultink
• 20 Managing biologics in lupus (5 September, 2024)

  Maria Dall’Era
• 21 Managing biologics in lupus (5 September, 2024)

  Alexandre Voskuyl
• 22 Incorporating patients’ perspectives in lupus management (5 September, 2024)

  Dalila Tremarias, Jeanette Andersen, Laurent Arnaud

Keynote

• 22 Lupus in my lifetime – as tears go by (5 September, 2024)

  Murray Urowitz

Prime time session: (HYBRID)

Part I: Baby you can drive my car-t cells...and other novel therapies

• 23 Origins of CAR-T cell therapy: hematologic perspective (5 September, 2024)

  Claire Roddie
• 24 CAR-T cell therapy for autoimmune diseases: lupus in focus (5 September, 2024)

  Ronald van Vollenhoven
• 25 Critical reflections on the use of CAR-T cells for lupus (5 September, 2024)

  Richard Furie
• 26 Combinations of biologics (5 September, 2024)

  David Isenberg
• 27 Bi-specific antibodies (5 September, 2024)

  Richard Furie

Part II: Lupus – hearts and bones … and eyes

• 28 Cardiac diseases in lupus (5 September, 2024)

  Wouter Kok
• 29 Lupus and the bones (5 September, 2024)

  Judith Bubbear
• 30 Lupus and the eyes (5 September, 2024)

  Joeri De Hoog

Plenary II: lupus activity and damage tools: new kids on the block

• 31 SLE-DAS (5 September, 2024)

  Luís Inês
• 32 Easy-BILAG (5 September, 2024)

  Ed Vital
• 33 Revised SDI (5 September, 2024)

  Ian Bruce
• 34 SLERPI (5 September, 2024)

  George Bertsias

Plenary III: renal failure: the long and winding road: (HYBRID)

• 35 My kidneys have given up – what happens now? (5 September, 2024)

  Zgjim Osmani
• 36 Managing poor adherence (5 September, 2024)

  Eleana Ntatsaki
• 37 Post-transplantation management (5 September, 2024)

  Y.K. Onno Teng